Skip to content

Molecular Basis of Pediatric Liver Cancer

Genetic and Molecular Basis of Pediatric Liver Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03959800
Enrollment
1600
Registered
2019-05-22
Start date
2015-06-22
Completion date
2035-06-30
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Childhood Liver Cancer, Embryonal Sarcoma of Liver (Disorder), Hepatoblastoma, Hepatocellular Carcinoma, Liver Malignant Tumors, Rhabdoid Tumor of Liver

Keywords

Hepatoblastoma, Hepatocellular Carcinoma, Pediatric Liver Cancer

Brief summary

The purpose of this retrospective and prospective project is to understand the molecular and genetic basis of liver cancer of childhood. Understanding the molecular and genetic bases of liver cancers can offer a better classification based on tumor biology, mechanisms and predisposition.

Detailed description

Pediatric liver cancers are rare, affecting at times no more than 1 in one million population. Understanding the molecular basis of these cancers is important in order to develop more accurate diagnoses and more effective treatments. Current classifications of these cancers are based on how these cancers look on diagnostic studies such as radiologic imaging or under the microscope. Such a classification system does not explain why a particular cancer has a different outcome from what is considered "usual" for that particular cancer. Nor does such a classification system explain why two different classes of cancers behave the same way. Understanding the genetic bases of liver cancers can offer a better classification based on tumor biology, mechanisms and predisposition. To achieve these goals, large numbers of such cancer patients or affected tissue must be collected. This is not possible in any single institution, or any single country. The current project will collect biological samples such as residual tumor tissue, saliva, or blood from affected patients and their biological parents and families, along with clinical information about the cancer. These biological samples will be used to study the genes and how these genes work in tumor tissue and in non-tumor tissue. The results of this study will permit childhood liver cancers to be categorized on the basis of common defects in genes and their function.

Interventions

None listed

Sponsors

University of Pittsburgh
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
0 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Prior or current treatment for a childhood liver tumor, malignant or benign, at age \<21 years. * Biological parents and siblings of eligible children.

Exclusion criteria

* No prior or current treatment for a childhood liver tumor. * Non-biological parents, legal guardians, or non-biological siblings of eligible children.

Design outcomes

Primary

MeasureTime frameDescription
Gene sequencingRecurrence free survival at 2 yearsDNA sequence variants
Gene expression analysisRecurrence free survival at 2 yearsDifferentially expressed genes
Status of genome-wide chromatin accessibilityDuration of active chemotherapy to two years after surgical treatmentchromatin accessibility
Epigenetic changeDuration of active chemotherapy to two years after surgical treatmentDifferential methylation
Tumor infiltrating cells which express immune checkpointsDuration of active chemotherapy to two years after surgical treatmentdifferentially enriched immune cells

Secondary

MeasureTime frameDescription
Response to chemotherapyDuration of active chemotherapy to two years after surgical treatmentSurvival

Countries

United States

Contacts

CONTACTMorgan Paul, BSN
Morgan.Paul2@upmc.edu(412) 692-8472
CONTACTDaniel Pieratt, MPA
pierattdw@upmc.edu(412) 692-6692

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 11, 2026